Citigroup
AVIR icon

Citigroup’s Atea Pharmaceuticals AVIR Stock Holding History

Citigroup’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.3K Buy
5,447
+1,658
+44% +$7.61K ﹤0.01% 4712
2025
Q4 		$13.5K Sell
3,789
-4,881
-56% -$15.5K ﹤0.01% 4970
2025
Q3 		$25.1K Sell
8,670
-26,649
-75% -$91K ﹤0.01% 4741
2025
Q2 		$127K Sell
35,319
-19,390
-35% -$57.8K ﹤0.01% 4300
2025
Q1 		$164K Sell
54,709
-6,225
-10% -$19.4K ﹤0.01% 4311
2024
Q4 		$204K Buy
60,934
+3,101
+5% +$10.3K ﹤0.01% 4400
2024
Q3 		$194K Buy
57,833
+38,636
+201% +$140K ﹤0.01% 4361
2024
Q2 		$63.5K Buy
19,197
+4,420
+30% +$16.5K ﹤0.01% 4456
2024
Q1 		$59.7K Buy
14,777
+2,284
+18% +$8.94K ﹤0.01% 4538
2023
Q4 		$38.1K Buy
12,493
+11,418
+1,062% +$34.6K ﹤0.01% 4661
2023
Q3 		$3.23K Sell
1,075
-40,729
-97% -$139K ﹤0.01% 4838
2023
Q2 		$156K Buy
41,804
+38,973
+1,377% +$146K ﹤0.01% 4016
2023
Q1 		$9.48K Sell
2,831
-5,357
-65% -$21.7K ﹤0.01% 4754
2022
Q4 		$39.4K Sell
8,188
-11,219
-58% -$56.8K ﹤0.01% 4350
2022
Q3 		$110K Buy
19,407
+246
+1% +$1.88K ﹤0.01% 4046
2022
Q2 		$136K Sell
19,161
-2,526
-12% -$17.2K ﹤0.01% 4049
2022
Q1 		$157K Sell
21,687
-19,280
-47% -$131K ﹤0.01% 4202
2021
Q4 		$366K Buy
40,967
+33,318
+436% +$519K ﹤0.01% 4000
2021
Q3 		$268K Buy
7,649
+4,209
+122% +$117K ﹤0.01% 3968
2021
Q2 		$74K Sell
3,440
-1,557
-31% -$46.8K ﹤0.01% 4630
2021
Q1 		$309K Buy
4,997
+2,250
+82% +$152K ﹤0.01% 3767
2020
Q4 		$115K Buy
+2,747
New +$88.5K ﹤0.01% 5427

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citigroup's AVIR Position: Q1 2026 in Review

Citigroup increased its Atea Pharmaceuticals (AVIR) stake by 44% in Q1 2026, buying an estimated $7.61K and bringing the position to 5,447 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4712.

Citigroup first reported a position in AVIR in Q4 2020 and has held it in 22 quarters since. The position peaked at $366K in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Citigroup held 5,447 shares of Atea Pharmaceuticals worth $29.3K as of Q1 2026.
  • Citigroup bought 1,658 Atea Pharmaceuticals shares in Q1 2026, an estimated $7.61K.
  • Atea Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4712 holding.
  • Citigroup first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Citigroup's Atea Pharmaceuticals position peaked at $366K in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.